P53 signature ---latent precancer of type II endometrial cancer
P53 mutations in endometrial glandular dysplasia (EmGD), a genetic evidence supporting its nature as a precancer of endometriuan serous carcinoma (ESC)
Luteinizing hormone (LH) with an opposing effect of follicle-stimulating hormone (FSH) via up-regulation of prohibitin